首页> 外文期刊>Nephron >Prevalence of chronic kidney disease and associated risk factors, and risk of end-stage renal disease: data from the PREVADIAB study.
【24h】

Prevalence of chronic kidney disease and associated risk factors, and risk of end-stage renal disease: data from the PREVADIAB study.

机译:慢性肾脏病和相关危险因素的患病率,以及终末期肾脏疾病的风险:来自PREVADIAB研究的数据。

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic kidney disease (CKD) is a growing public health problem. However, data on risk factors and prevalence of CKD exist only in a small number of countries. Portugal has the highest incidence of end-stage renal disease (ESRD) among European countries, but there are huge disparities among countries. Whether these disparities reflect differences in risk factors, prevalence of CKD or other factors is currently unknown.We analyzed data from a nationally representative sample of 5,167 subjects, and estimated the prevalence of CKD and associated risk factors, and combined these prevalence estimates with available data on ESRD.The prevalence of risk factors such as diabetes (11.7%), obesity (33.7%), and metabolic syndrome (41.5%) was similar to that in the US, but greater than in most European countries. The prevalence of CKD stages 3-5 was 6.1%, which is similar to that in other Western countries. The risk of ESRD was greater than in other European countries, but lower than in the US.The high incidence of ESRD among the Portuguese population is not due to a greater prevalence of CKD. A higher rate of progression associated with the high prevalence of risk factors may account for the high incidence of ESRD. The role of unmeasured factors needs to be evaluated in further studies.
机译:慢性肾脏病(CKD)是一个日益严重的公共卫生问题。然而,关于危险因素和CKD患病率的数据仅在少数国家存在。在欧洲国家中,葡萄牙的终末期肾病(ESRD)发病率最高,但各国之间存在巨大差异。目前尚不清楚这些差异是否反映出危险因素,CKD患病率或其他因素的差异。我们分析了5167名全国代表性样本的数据,估算了CKD患病率和相关的危险因素,并将这些患病率估计值与可用数据相结合糖尿病(11.7%),肥胖(33.7%)和代谢综合征(41.5%)等危险因素的发生率与美国相似,但高于大多数欧洲国家。 CKD 3-5阶段的患病率为6.1%,与其他西方国家相似。 ESRD的风险高于其他欧洲国家,但低于美国。葡萄牙人群中ESRD的高发病率并不是由于CKD的患病率更高。与较高的危险因素患病率相关的较高进展率可能是ESRD的高发病率的原因。未测因素的作用需要进一步研究评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号